Phase 2 Macular Degeneration Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina and leak fluid, damaging central vision)
• People whose wet AMD has been treated only with anti-VEGF eye injections (a common type of medication injected into the eye to slow abnormal blood vessel growth); having other eye conditions such as diabetic retinopathy or blocked eye veins is acceptable, as long as those conditions are not also being treated with these injections
• People who still have fluid under or within the retina despite having received at least three consecutive anti-VEGF eye injections
• People who have not previously had bad reactions or side effects from tetracycline-type antibiotics (a family of medicines that includes doxycycline)

Who may not be able to join:

• People with a history of inflammation inside the eye (such as uveitis or infection inside the eye) or who currently have eye inflammation
• People with a significant scar-like membrane over the retina or a hole in the central part of the retina that distorts its normal structure
• People with cloudiness inside the eye that prevents clear imaging of fluid on the type of eye scan used in this trial (called OCT)
• People who have had any eye surgery (including certain laser procedures) within the past 3 months, or who are expected to need eye surgery within 9 months of joining the trial
• People who have had a steroid injection around the outside of the eye (in either eye) within the past 6 months
• People who have had a specific steroid medication (triamcinolone acetonide) injected inside the study eye within the past 4 months
• People who have another eye condition (apart from AMD) in the study eye that, in the trial doctor's opinion, could affect vision during the study — examples given include blocked retinal veins, eye inflammation, a type of glaucoma caused by abnormal blood vessels, or a condition called Irvine-Gass Syndrome
• People whose abnormal blood vessel growth under the retina is caused by something other than wet AMD
• People who are unlikely to be able to attend follow-up appointments at 6 and 9 months after joining
• People who miss two or more injections in a row during the 6-month treatment period
• People who are likely to need to switch to a different eye injection medication or a different treatment (such as a light-based therapy called photodynamic therapy) during the 9-month trial period
• People whose retinal fluid is linked to a late-stage AMD change called geographic atrophy, or to a type of scarring called a disciform scar
• People whose retinal fluid is not caused by abnormal blood vessel growth under the retina (confirm with trial site)
• People currently being treated for Irvine-Gass Syndrome (a condition involving eye swelling that can occur after cataract surgery)
• People whose general health is considered unstable by the trial doctor — for example, poorly controlled blood sugar or blood pressure, heart or blood vessel disease, or any condition making it unlikely the person could complete 9 months in the trial
• People with significantly reduced kidney function (defined as a specific blood test result above a certain level — confirm with trial site)
• People with very high blood pressure (systolic above 180 mmHg or diastolic above 110 mmHg)
• People who have previously had headaches as a side effect of tetracycline-type medications
• People with a history of a condition called pseudotumor cerebri (a condition involving increased pressure in the fluid around the brain)
• People who have taken any tetracycline-type medication within the past 6 months
• People who are pregnant or planning to become pregnant within the 9 months of the trial; women who could potentially become pregnant will be asked to take a pregnancy test
• Women of childbearing potential who are sexually active but not using an accepted form of contraception (such as an intrauterine device, hormonal contraception, or a barrier method) throughout the study; because doxycycline (the study drug) may reduce the effectiveness of hormonal contraceptives, women using hormonal contraception will be required to also use a second method of contraception during the trial
• People with a known allergy or intolerance to doxycycline, tetracycline-type medicines, or any ingredient in the study drug or placebo
• People taking certain other medications — including phenytoin, barbiturates, carbamazepine, digoxin, or isotretinoin — or people with certain stomach or digestive conditions (such as delayed stomach emptying, prior stomach removal surgery, or gastric bypass surgery), due to the way these factors can affect how the study drug is processed by the body
• People taking strontium, acitretin, or tretinoin, due to the risk of serious interactions with the study drug
• People with abnormal liver enzyme levels at the start of the trial (these individuals would be referred to their usual doctor for clearance before participation could be considered)

Important: Always verify eligibility with the trial site directly before applying.